This article is more than 5 years old. Information may no longer be current.

Anifrolumab moves into phase 3 for systemic lupus erythematosus treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AstraZeneca has announced it will move MedImmune’s anifrolumab into a phase 3 trial this year for the treatment of moderate-to-severe systemic lupus erythematosus, according to a company press release and quarterly report.

The type 1 interferon inhibitor met its primary endpoint of a reduction global disease activity score in patients with systemic lupus erythematosus (SLE) after 6 months in a phase 2B trial. It is believed anifrolumab binds to subunit 1 of the type 1 interferon receptor, which inhibits activity at the receptor. Data from the trial are expected to be presented at an unspecified scientific meeting later in the year, the release stated.

Unlike anifrolumab, the company’s interferon inhibitor sifalimumab will not move forward from a recent phase 2B trial, according to the quarterly report.

“The company does not currently intend to further develop sifalimumab in lupus, and any future decisions about this molecule in other potential indications will be made based on further examination of available data,” the company wrote in its first-quarter earnings report.

Reference: www.astrazeneca.com.